Evaluation Of Clinical Treatment Effect Of Mongolian Medicine On Type Of Heyi-excess Parkinson’s Disease

Objective:This study uses Mongolian medicine to treat patients with"Heyi-excess"type(赫依偏盛型)Parkinson’s disease,and discussed the clinical efficacy and safety of Mongolian medicine for Parkinson’s disease.Methods: From December 2020 to March 2023,72 patients with Parkinson’s disease who met the inclusion and exclusion criteria were collected from Inner Mongolia International Mongolian Hospital,and randomly divided into two groups with 36 patients in each group as the control group and the experimental group.The control group was treated with Levodopa and Benserazide Hydrochlo-ride tablets,and the dose was adjusted according to clinical symptoms and adverse reactions.The experimental group was given the dialectical treatment of Mongolian medicine on the basis of Levodopa and Benserazide Hydrochlo-ride tablets.The treatment course was 90 days.The two groups of patients were grade the Unified Parkinson’s Rating Scale(UPDRS3.0),the Modified Hoehn-Yahr Scale,the SCHWAB&ENGLAND Daily Activity Ability Scale,the Parkinson’s Sleep Scale(PDSS),and the Bristol Fecal Scale before and after treatment.The scores of the two groups were compared before and after the treatment,and the adverse reactions during the treatment were recorded,so as to evaluate the clinical efficacy and safety of the combination of Mongolian medicine in treating patients with "Heyi-excess" type Parkinson’s disease.Results: There were 72 patients in the original plan,43 were enrolled,3 were dropout,40 were actually completed,including 21 were in the test group,and 19 were in the control group.(1)UPDRS I-IV score: After treatment,there were significant differences in UPDRSⅰ～ⅳ scores between the two groups(P<0.05).Compared with the control group,the UPDRS I and IV scores in the test group decreased more significantly 90 days after treatment(P<0.05).(2)PDSS score: after treatment,the score of the control group were decreased,while the score of the test group increased significantly,the difference has statistics significance(P<0.05).(3)Bristol classification table: the number of constipated patient in the control group increased before and after treatment,while the number of constipation in the test group decreased significantly.(4)Modified H-Y grading: At 90 days after treatment,the modified There was no significant difference in H-Y score between the two groups after treatment(P >0.05).Conclusion:The combination of Mongolian medicine and Levodopa and Benserazide Hydrochloride Tablets is effective in the treatment of patients with "Heyi-excess" type Parkinson’s disease.and that was effectively improved the inapparent movement symptoms of patients with Parkinson’s disease,especially the symptoms of mental activity,sleep disorder and constipation,improve the quality of life of patients with better safety.